New Acquisition Expands Sequencing Install Base to 37 Illumina Genome Analyzers

Illumina, Inc. has announced that the Wellcome Trust Sanger Institute has purchased 11 additional Genome Analyzers, increasing the organization's total number of the Illumina sequencing platform to 37.

The continued scale up on the Genome Analyzer will support the Sanger Institute's many initiatives, such as its contribution to the 1000 Genome Project.

"The Sanger Institute has an important international role in producing and analyzing genomic data. That role is founded in DNA sequencing and we will meet new challenges by investing in appropriate new technologies," said Professor Julian Parkhill, Ph.D., Director of Sequencing at the Wellcome Trust Sanger Institute.

"We are expanding our ability to contribute to major projects on human and mouse genome resequencing, pathogen genomics and genetics, and cancer genetics and to carry out our own research programmes within the Institute strategy," said Parkhill.

Generating over 20GB of data on internal systems, the Genome Analyzer offers the highest rate of daily output and the user friendly workflow. The Genome Analyzer also offers a set of supported applications, including those used to profile and discover novel miRNA, to create a high-resolution genome-wide map of DNA-protein binding sites.